Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome
Florence Wong, Kevin Moore, Jasper Dingemanse, Rajiv Jalan – 26 December 2007 – Renal vasoconstriction is a key factor in the development of hepatorenal syndrome (HRS) and may be secondary to increased activities of endothelin‐1, a potent renal vasoconstrictor.